Offshore Trusts ManCo List Funds by Name Funds by Category Word Search FAQ

Franklin Biotechnology Discovery Fund Franklin Templeton Investment Funds Franklin Biotechnology Discovery Fund News Regional Portfolio Structure(Semi-Annual Comparison) Sectorial Portfolio Structure(Semi-Annual Comparison) Price   Ranking Sector: USA-Equity-Unclassified Size: (USD) 1 380 000 000   Sector Rank: 1 out of 3 (lump sum over 3 years to 28 Feb 2025)   Overall Rank: 97 out of 486 (lump sum over 3 years to 28 Feb 2025)   R20000 invested on 28 Feb 2022 was worth R29 878 at 28 Feb 2025 (14.32% annual compound return)   R5000 per month since 28 Feb 2022 was worth R213 707 at 28 Feb 2025 (10.90% annual return compounded monthly)   Please note that offshore fund performance figures are calculated from NAV prices (ie, equivalent to sell-to-sell) and therefore not directly comparable to domestic fund performance figures on this site.   Management Evan McCulloch, CFA, Franklin Advisors Inc Evan McCulloch is a vice president and portfolio manager for Franklin Advisers, Inc. He manages the Franklin Biotechnology Discovery Fund and the Franklin Biotechnology Fund. Mr McCulloch also specialises in research analysis of the health care industry; including pharmaceuticals, health care information systems/internet and health care providers. Mr McCulloch joined Franklin Templeton Investments in 1992 as a management trainee. He received a bachelor's degree in economics from the University of California at Berkeley. He is a Chartered Financial Analyst (CFA) and a member of the Association for Investment Management and Research (AIMR) and the Security Analysts of San Francisco (SAs/f).   Steve Kornfeld   Christopher Jay Lee   Wendy Lam   Akiva Felt   Focus and Objective The investment objective of the fund is capital growth by investing in equity securities of biotechnology companies and discovery research firms mainly located in the USA substantial portion of its assets will be in smaller capitalisation companies (those with market capitalisation of less than USD2bn). For the fund's investment purposes, a biotechnology company is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities based on the company's most recent fiscal year. Biotechnology activities are research, development, manufacture and distribution of various biotechnological or biomedical products, services and processes. This may include companies involved with genomics, genetic engineering and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals and agriculture. To the extent that the fund invests in debt securities, it generally buys securities that are rated investment grade or unrated securities that it determines to be of comparable quality. Investment grade debt securities are rated in the top four ratings categories by independent ratings organisations such as Standard & Poor's Corporation or Moody's Investors Service Inc. The fund anticipates that under normal conditions, it will invest more of its assets in US securities than in those of any other single country although the fund may have more than 50% of its total assets in non-US securities. The manager may take a temporary defensive position when it believes the securities trading markets or the economies of countries where the fund invests are experiencing excessive volatility or prolonged general decline, or other adverse conditions exist. Under these circumstances, the fund may be unable to pursue its investment goal.   Technical Overview Benchmark: NASDAQ Biotechnology index Administration Fee Management fee (p.a.): 1.51% Allows debit orders No Maximum Exit Fee Annual Registrar Fee 0.20% Minimum lump sum: $5 000 Base currency: USD Minimum monthly: $1 000 Broker Comm. Payable Yes Minimum Exit Fee Custodian Fee Number of holdings: 65 Domicile Luxembourg Original price: USD 100.00 Exit fee charge: No Performance fee: Formation date: 03 Apr 2000 Pricing system: Forward Is this fund a roll-up? Yes Promotional Fee   Top holdings on 31 Dec 2024 Share (Sector) Value (USD) % of fund AMGEN (Healthcare) 83 628 000 6.06% VERTEXPHARM (Healthcare) 80 454 000 5.83% GILEADSCIENCE (Healthcare) 77 970 000 5.65% REGENERONPHA (Healthcare) 77 004 000 5.58% JAZZPHARMA (Healthcare) 46 368 000 3.36% ASTRAZENECA (Healthcare) 39 054 000 2.83% TOTALS 404 478 000 29.31%

Site Last Updated: 10 March 2025 © 1999-2006 Profile Media . All rights reserved. JSE and the JSE logo are trade marks of the JSE. Legal Notices | PAIA Manual